Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
New research indicates that extracellular aminoacyl-tRNA synthetases contribute to the pathogenesis of rheumatoid arthritis by functioning as alarmins, and could be a novel therapeutic target.
Researchers have developed ‘urchin-like’ ceria nanoparticles with inherent antioxidant properties that efficiently carry therapeutic microRNA, enabling gene therapy following intra-articular injection in a mouse model of osteoarthritis.
Platelet activity and the formation of monocyte–platelet aggregates contribute to the production of IL-1β and the development of cardiovascular lesions in Kawasaki disease.
In a phase III trial, the oral Janus kinase inhibitor baricitinib was safe and effective in patients with juvenile idiopathic arthritis who previously had an inadequate response to DMARD therapy.
New findings suggest that interosseous tendon inflammation is already present in individuals with clinically suspect arthralgia and is linked to an increased risk of developing clinical arthritis.
A new report indicates that low back pain remains the leading cause of disability worldwide, and that case numbers are expected to increase substantially in the coming decades.
New findings implicate TAp63 as a potential target of methotrexate in T cells, providing insight in the mechanism of action of this drug, including its suppressive effects on regulatory T cells.
New findings suggest that neutrophil extracellular traps and their components have a functional role as triggers of IL-17-mediated inflammation and associated bone destruction in periodontitis.
Researchers have co-cultured human mesenchymal stromal cells and monocytes to generate bone-like structures that have the potential to facilitate the study of bone remodelling in vitro.
The ACR has developed its first guideline for managing rheumatoid arthritis using integrative interventions, to aid in decision-making regarding such approaches alongside pharmacological treatment.
New research demonstrates that regulatory T cells in gut and joint tissues differ in their response to and ability to control TNF-mediated inflammation.
Cognitive functional therapy is a safe, effective and low-cost intervention for individuals with persistent disabling low back pain, according to results from the phase III RESTORE trial.
Results of a population-based cohort study of more than 20 million individuals in the UK reveal that the incidence of several autoimmune disorders, and of rheumatic diseases in particular, continues to increase over time.
Magnesium ascorbyl phosphate is a stable derivative of ascorbic acid that has now been shown to promote bone formation via stimulation of the CAMKIIα pathway.
A new treatment for osteoarthritis that combines cells from the patient in vitro prior to intra-articular injection has demonstrated beneficial effects on arthritic joints in a compassionate use study.
In a retrospective study, risk–benefit analyses suggest that primary prophylaxis against Pneumocystis jirovecii pneumonia is beneficial in patients receiving rituximab and high-dose glucocorticoids.
In a retrospective study, biologic DMARD therapy was associated with faster control of immune checkpoint inhibitor-associated arthritis but also with a shorter time to cancer progression, compared with methotrexate therapy.
Clinical and molecular analysis of autoantibodies against the endonuclease DNase1L3 in patients with systemic lupus erythematosus led to the identification of a subset of pathogenetic antibodies that are cross-reactive with double-stranded DNA.
